NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Metagen Therapeutics, Inc.

Metagen Therapeutics, Inc.

Private
TsuruokaHealthcare & Life Scienceshttps://www.metagentx.com/

Last Round

Series B

Feb 25, 2026

Total Funding Raised

$51.71M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Metagen Therapeutics, Inc. is a biotechnology company that advances medicine and drug discovery based on human gut microbiome research.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

fecal microbiota transplantationFMTmicrobiome therapeuticsgut microbiota bankpoop transplantmicrobiome drug discoveryoral FMTbiotech CROmetagenomicsclinical-stage biotechmicrobiome researchdrug discovery platformAI drug discoverybiobank

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Metagen Therapeutics, Inc. Comparables

Compare Metagen Therapeutics, Inc. with similar companies based on industry and business-model similarity.

Metagen Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
EnteroBiotix
81%
BiomeBank
81%
MRM Health
80%

Metagen Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 25, 2026
Series BSep 8, 2025
Series AJun 15, 2023
Pre SeedJun 30, 2022
SeedMar 17, 2021

Key People

Founding team and executive leadership

Taku Nakahara

Co-founder CEO

Founding Team

Takashi Nishino

CFO

Executive Team

Metagen Therapeutics, Inc. Investors

Notable investors and investment history

Metagen Therapeutics, Inc. investors
InvestorRounds
JAFCO Group Co., Ltd.Seed, Series A, Pre Seed, Series B
Sparx Asset ManagementSeries A, Series B
Tokai Tokyo Investment Co., Ltd.Series B
Keio Innovation InitiativeSeed, Series A, Pre Seed, Series B
Mizuho CapitalSeries A, Series B
Arcus InvestmentSeries B
日本ベンチャーキャピタル株式会社Series A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 10, 2025

    Company is in the N-2 stage, indicating a potential listing in approximately two years.

  • Nov 10, 2025

    Partnering with Juntendo University for ulcerative colitis research.

Metagen Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Metagen Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Metagen Therapeutics, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersTsuruoka
Employee Range17
Year Founded2020
Last FundingFeb 25, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.